Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo ± Yervoy with TACE in intermediate HCC (China)
CTR20211605Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Jul 2021; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20211605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211605.